Get the Stockscreener App
18.65
1.52%
-0.30
Moonlake Immunotherapeutics stock is traded at $18.65, with a volume of 380.11K.
It is down -1.52% in the last 24 hours and up +4.26% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
See More
Previous Close:
$18.95
Open:
$19
24h Volume:
380.11K
Relative Volume:
0.33
Market Cap:
$1.56B
Revenue:
-
Net Income/Loss:
$-230.32M
P/E Ratio:
-5.2894
EPS:
-3.5259
Net Cash Flow:
$-196.04M
1W Performance:
-6.27%
1M Performance:
+4.26%
6M Performance:
+67.07%
1Y Performance:
-61.83%
1-Day Range:
$18.53
$19.26
1-Week Range:
$18.53
$20.12
52-Week Range:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
18.64 | 1.63B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
527.99 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.54 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.19 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.63 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.17 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Upgrade | Wolfe Research | Underperform → Outperform |
| Mar-19-26 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Jan-15-26 | Downgrade | Goldman | Neutral → Sell |
| Jan-09-26 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-01-25 | Downgrade | Goldman | Buy → Neutral |
| Sep-30-25 | Downgrade | Citigroup | Buy → Neutral |
| Sep-30-25 | Downgrade | Wolfe Research | Outperform → Underperform |
| Sep-29-25 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-29-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-29-25 | Downgrade | Stifel | Buy → Hold |
| Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
MoonLake Reports Positive 52-Week Phase 3 Data for Sonelokimab in Hidradenitis Suppurativa - Dermatology Times
What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors - Kavout | AI
Top biotech stocks to watch in second half of 2026, says Clear Street - Investing.com South Africa
MLTX Maintained by Leerink Partners -- Price Target Raised to $2 - GuruFocus
Leerink raises Moonlake stock price target on HS drug data By Investing.com - Investing.com South Africa
Leerink raises Moonlake stock price target on HS drug data - Investing.com
Form 144 MoonLake Immunotherapeutics For: 30 June By Investing.com - Investing.com Canada
MLTX (Nasdaq) Rule 144 notice shows 150,000 Class A shares sale (04/10/2026) - Stock Titan
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites - Stocktwits
MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa - Yahoo Finance
MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism? - Stocktwits
Form 13D/A MoonLake Immunotherapeutics For: 29 June By Investing.com - Investing.com South Africa
BVF group reports 19.7% MoonLake Immunotherapeutics (MLTX) stake - Stock Titan
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits
MoonLake Immunotherapeutics (MLTX) Is Down 10.2% After $200M Follow-On Offering To Fund Sonelokimab PushHas The Bull Case Changed? - simplywall.st
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Ove - The National Law Review
MoonLake Immunotherapeutics Completes $200 Million Public Offering of Class A Shares - Global Legal Chronicle
Did You Lose Money on MoonLake Immunotherapeutics (MLTX)? Levi - The National Law Review
Levi & Korsinsky Urges MoonLake (MLTX) Shareholders to Act Before Lead Plaintiff Deadline December 15, 2025 - The National Law Review
Recover Investment Losses: Class Action Initiated Against MoonLake Immunotherapeutics (MLTX) - The National Law Review
Lost Money on MoonLake Immunotherapeutics (MLTX)? Join Class Acti - The National Law Review
Shareholders of MoonLake Immunotherapeutics (MLTX): Protect Your - The National Law Review
MLTX ALERT: Block & Leviton LLP Announces The Filing of a Class A - The National Law Review
10 Best Biotech Stocks to Buy According to Analysts - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
MoonLake Immunotherapeutics (MLTX) LawsuitInvestors Urged to C - The National Law Review
MLTX stock extends pullback after biggest rally in over 6 months following skin disease trial data — a look at the latest development - MSN
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday - AOL.com
MoonLake Immunotherapeutics Class A Actuals & Estimates (NASDAQ:MLTX) - TradingView
Why MoonLake Immunotherapeutics stock wilted on Wednesday - MSN
(MLTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits
MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion (NASDAQ:MLTX) - Seeking Alpha
MoonLake Immunotherapeutics prices $200M public offering of Class A shares - MSN
Enterprise value to EBIT forward of MoonLake Immunotherapeutics – NASDAQ:MLTX - TradingView
MoonLake Expects Offering to Close on or About June 25 >MLTX - Moomoo
United StatesMintz Advises On MoonLake Immunotherapeutics’ $200 Million Public Offering - Mondaq
Enterprise value to EBIT forward of MoonLake Immunotherapeutics – BOATS:MLTX - TradingView
MoonLake Immunotherapeutics Class A Actuals & Estimates (BOATS:MLTX) - TradingView
MoonLake Immunotherapeutics Class A Actuals & Estimates (BIVA:MLTX/N) - TradingView
MLTX Forecast — Price Target — Prediction for 2027 - TradingView
MLTX/N Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of MoonLake Immunotherapeutics – NASDAQ:MLTX - TradingView
How Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On Offering - Yahoo Finance
MoonLake Immunotherapeutics Launches $200 Million Equity Offering Underwritten by Leerink Partners - TradingView
MoonLake Immunotherapeutics (NASDAQ: MLTX) launches $200M equity and warrant sale - Stock Titan
Price to book forward of MoonLake Immunotherapeutics – NASDAQ:MLTX - TradingView
Price to sales forward of MoonLake Immunotherapeutics – BOATS:MLTX - TradingView
Enterprise value to revenue forward of MoonLake Immunotherapeutics – NASDAQ:MLTX - TradingView
Enterprise value to revenue forward of MoonLake Immunotherapeutics – BOATS:MLTX - TradingView
Price to earnings forward of MoonLake Immunotherapeutics – NASDAQ:MLTX - TradingView
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):